What is Curi Bio?
Curi Bio operates at the intersection of biotechnology and data science, providing an integrated platform that combines 3D tissue models with automated functional analysis. By leveraging human stem cell technology, the company enables biopharmaceutical organizations to generate highly predictive data regarding drug safety, efficacy, and potency. This approach effectively reduces the reliance on traditional, less accurate preclinical models, thereby streamlining the drug development pipeline and mitigating risks associated with late-stage clinical failures. Curi Bio's core value proposition lies in its ability to deliver actionable insights that inform high-stakes R&D decision-making for global pharmaceutical end users.
How much funding has Curi Bio raised?
Curi Bio has raised a total of $26.1M across 3 funding rounds:
Debt
$150K
Series A
$16M
Series B
$10M
Debt (2020): $150K with participation from PPP
Series A (2021): $16M led by DS Asset Management, UTC Investment, and DYNAMK CAPITAL
Series B (2025): $10M supported by DreamCIS
Key Investors in Curi Bio
DS Asset Management
An investment management firm that focuses on deep insights into companies and industries to foster trusted partnerships with clients for mutual growth.
DYNAMK CAPITAL
A venture capital firm specializing in growth-stage investments within the life sciences and bioprocessing sectors.
DreamCIS
A clinical development services provider offering comprehensive solutions for clinical trials and medical device consulting across various therapeutic areas.
What's next for Curi Bio?
With this latest strategic investment, Curi Bio is well-positioned to scale its operations and expand its suite of 3D tissue models. The company is expected to focus on enhancing its automated data analysis capabilities, further integrating its platform into the workflows of major global pharmaceutical partners. As the industry shifts toward more human-centric drug discovery, Curi Bio's focus on clinically relevant functional analyses will likely serve as a primary driver for future growth and market penetration. The firm remains committed to accelerating the development of safer, more effective medicines through technological innovation and strategic partnerships.
See full Curi Bio company page
